Irina Staatz-Granzer, Ph.D. was Chairwoman of the Supervisory Board of the Company since January 1, 2024 and is now Chairwoman of the Board of Directors since May 2025.
Dr. Staatz-Granzer has held business development positions at Hermal (subsidiary of Merck KGaA), Boots Healthcare International, Knoll (BASF Pharma, later Abbott) and as CEO of Scil Technology Gmbh, CEO of U3 Pharma AG and CEO of Blink Biomedical SAS. Ms. Staatz-Granzer also serves as Chairman of PLCD (German Pharma Licensing Club).
She founded and is currently CEO of Staatz Business Development & Strategy. She is also member of the Supervisory Board of Aelis Farma SAS.
Dr. Staaz-Granzer received a degree in pharmacy from Philipps-Universität Marburg (Germany) and a Ph.D. from the University of Tübingen (Germany).